WEKO3
インデックスリンク
アイテム
Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer
https://doi.org/10.24517/00062695
https://doi.org/10.24517/00062695bee59766-f277-4e76-86bf-40dd08bfa059
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
ME-PR-MAEDA-D-40402.pdf (2.6 MB)
|
.png)
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||
|---|---|---|---|---|---|---|---|---|
| 公開日 | 2021-06-28 | |||||||
| タイトル | ||||||||
| タイトル | Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer | |||||||
| 言語 | ||||||||
| 言語 | eng | |||||||
| 資源タイプ | ||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||
| 資源タイプ | journal article | |||||||
| ID登録 | ||||||||
| ID登録 | 10.24517/00062695 | |||||||
| ID登録タイプ | JaLC | |||||||
| 著者 |
Oki, Shinya
× Oki, Shinya× Sone, Kenbun× Oda, Katsutoshi× Hamamoto, Ryuji× Ikemura, Masako× Maeda, Daichi× Takeuchi, Makoto× Tanikawa, Michihiro× Mori-Uchino, Mayuyo× Nagasaka, Kazunori× Miyasaka, Aki× Kashiyama, Tomoko× Ikeda, Yuji× Arimoto, Takahide× Kuramoto, Hiroyuki× Wada-Hiraike, Osamu× Kawana, Kei× Fukayama, Masashi× Osuga, Yutaka× Fujii, Tomoyuki |
|||||||
| 著者別表示 |
前田, 大地
× 前田, 大地
|
|||||||
| 提供者所属 | ||||||||
| 内容記述タイプ | Other | |||||||
| 内容記述 | 金沢大学医薬保健研究域医学系 | |||||||
| 書誌情報 |
Oncotarget 巻 8, 号 25, p. 40402-40411, 発行日 2017-03-17 |
|||||||
| ISSN | ||||||||
| 収録物識別子タイプ | ISSN | |||||||
| 収録物識別子 | 1949-2553 | |||||||
| DOI | ||||||||
| 関連タイプ | isIdenticalTo | |||||||
| 識別子タイプ | DOI | |||||||
| 関連識別子 | 10.18632/oncotarget.16316 | |||||||
| 出版者 | ||||||||
| 出版者 | Impact Journals LLC | |||||||
| 抄録 | ||||||||
| 内容記述タイプ | Abstract | |||||||
| 内容記述 | The histone methyltransferase EZH2, a key epigenetic modifier, is known to be associated with human tumorigenesis. However, the physiological importance of EZH2 and its clinical relevance in endometrial cancer remain unclear. Hence, in the present study, we investigated the expression and function of EZH2 in endometrial cancer. In a quantitative real-time PCR analysis of 11 endometrial cancer cell lines and 52 clinical endometrial cancer specimens, EZH2 was significantly overexpressed in cancer cells and tissues compared to that in corresponding normal control cells and tissues. Kaplan-Meier survival analysis using data of the TCGA RNA-seq database and tissue microarrays (TMAs) indicated that EZH2 overexpression is associated with endometrial cancer prognosis. In addition, knockdown of EZH2 using specific siRNAs resulted in growth suppression and apoptosis induction of endometrial cancer cells, accompanied by attenuation of H3K27 trimethylation. Consistent with these results, treatment with GSK126, a specific EZH2 inhibitor, suppressed endometrial cancer cell growth and decreased the number of cancer cell colonies. Furthermore, GSK126 showed additive effects with doxorubicin or cisplatin, which are conventional drugs for treatment of endometrial cancer. Further studies should explore the therapeutic potential of inhibiting EZH2 in patients with endometrial cancer. © Oki et al. | |||||||
| 権利 | ||||||||
| 権利情報 | Copyright © Impact Journals LLC | |||||||
| 著者版フラグ | ||||||||
| 出版タイプ | VoR | |||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||
| 関連URI | ||||||||
| 識別子タイプ | URI | |||||||
| 関連識別子 | http://www.impactjournals.com/oncotarget/ | |||||||
| 関連名称 | http://www.impactjournals.com/oncotarget/ | |||||||
| 関連URI | ||||||||
| 識別子タイプ | URI | |||||||
| 関連識別子 | https://www.oncotarget.com/article/16316/text/ | |||||||
| 関連名称 | https://www.oncotarget.com/article/16316/text/ | |||||||
